Current developments and applications of microfluidic technology toward clinical translation of nanomedicines

Research output: Contribution to journalReview ArticleScientificpeer-review

Abstract

Nanoparticulate drug delivery systems hold great potential for the therapy of many diseases, especially cancer. However, the translation of nanoparticulate drug delivery systems from academic research to the industrial and clinical practice has been slow. This slow translation can be ascribed to the high batch-to-batch variations and insufficient production rate of the conventional methods, and the lack of technologies for rapid screening of nanoparticulate drug delivery systems with high correlation to the in vivo tests. These issues can be addressed by the microfluidic technologies. For example, microfluidics can not only produce nanoparticles in a well-controlled, reproducible, and high-throughput manner, but also create 3D environments with continuous flow to mimic the physiological and/or pathological processes. This review provides an overview of the microfluidic devices developed to prepare nanoparticulate drug delivery systems, including drug nanosuspensions, polymer nanoparticles, polyplexes, structured nanoparticles and theranostic nanoparticles. We also
highlight the recent advances of microfluidic systems in fabricating the increasingly realistic models of the in vivo milieu for rapid screening of nanoparticles. Overall, the microfluidic technologies offer a promise approach to accelerate the clinical translation of nanoparticulate drug delivery systems.
Original languageEnglish
JournalAdvanced Drug Delivery Reviews
Volume128
Pages (from-to)54-83
Number of pages30
ISSN0169-409X
DOIs
Publication statusPublished - 15 Mar 2018
MoE publication typeA2 Review article in a scientific journal

Fields of Science

  • 317 Pharmacy
  • High throughput prepar ation
  • Lab-on-a-chip
  • Nanomedicines
  • Drug delivery
  • Organ-on-a-chip
  • Formulation screening
  • ON-A-CHIP
  • BLOCK-COPOLYMER NANOPARTICLES
  • CONFINED IMPINGING JETS
  • CEFUROXIME AXETIL NANOPARTICLES
  • POLYMER HYBRID NANOPARTICLES
  • PARTICLE-CELL INTERACTIONS
  • HIGH-THROUGHPUT PRODUCTION
  • DRUG-LOADED NANOPARTICLES
  • GAS-LIQUID FLOW
  • IN-VIVO
  • High throughput preparation
  • Lab-on-a-chip
  • Nanomedicines
  • Drug delivery
  • Organ-on-a-chip
  • Formulation screening
  • ON-A-CHIP
  • BLOCK-COPOLYMER NANOPARTICLES
  • CONFINED IMPINGING JETS
  • CEFUROXIME AXETIL NANOPARTICLES
  • POLYMER HYBRID NANOPARTICLES
  • PARTICLE-CELL INTERACTIONS
  • HIGH-THROUGHPUT PRODUCTION
  • DRUG-LOADED NANOPARTICLES
  • GAS-LIQUID FLOW
  • IN-VIVO

Cite this

@article{6be3e12e14a847b5a2dea0115ab293ef,
title = "Current developments and applications of microfluidic technology toward clinical translation of nanomedicines",
abstract = "Nanoparticulate drug delivery systems hold great potential for the therapy of many diseases, especially cancer. However, the translation of nanoparticulate drug delivery systems from academic research to the industrial and clinical practice has been slow. This slow translation can be ascribed to the high batch-to-batch variations and insufficient production rate of the conventional methods, and the lack of technologies for rapid screening of nanoparticulate drug delivery systems with high correlation to the in vivo tests. These issues can be addressed by the microfluidic technologies. For example, microfluidics can not only produce nanoparticles in a well-controlled, reproducible, and high-throughput manner, but also create 3D environments with continuous flow to mimic the physiological and/or pathological processes. This review provides an overview of the microfluidic devices developed to prepare nanoparticulate drug delivery systems, including drug nanosuspensions, polymer nanoparticles, polyplexes, structured nanoparticles and theranostic nanoparticles. We also highlight the recent advances of microfluidic systems in fabricating the increasingly realistic models of the in vivo milieu for rapid screening of nanoparticles. Overall, the microfluidic technologies offer a promise approach to accelerate the clinical translation of nanoparticulate drug delivery systems.",
keywords = "317 Pharmacy, High throughput prepar ation, Lab-on-a-chip, Nanomedicines, Drug delivery, Organ-on-a-chip, Formulation screening, ON-A-CHIP, BLOCK-COPOLYMER NANOPARTICLES, CONFINED IMPINGING JETS, CEFUROXIME AXETIL NANOPARTICLES, POLYMER HYBRID NANOPARTICLES, PARTICLE-CELL INTERACTIONS, HIGH-THROUGHPUT PRODUCTION, DRUG-LOADED NANOPARTICLES, GAS-LIQUID FLOW, IN-VIVO, High throughput preparation, Lab-on-a-chip, Nanomedicines, Drug delivery, Organ-on-a-chip, Formulation screening, ON-A-CHIP, BLOCK-COPOLYMER NANOPARTICLES, CONFINED IMPINGING JETS, CEFUROXIME AXETIL NANOPARTICLES, POLYMER HYBRID NANOPARTICLES, PARTICLE-CELL INTERACTIONS, HIGH-THROUGHPUT PRODUCTION, DRUG-LOADED NANOPARTICLES, GAS-LIQUID FLOW, IN-VIVO",
author = "Dongfei Liu and Hongbo Zhang and Flavia Fontana and Hirvonen, {Jouni Tapio} and {Almeida Santos}, Helder",
year = "2018",
month = "3",
day = "15",
doi = "10.1016/j.addr.2017.08.003",
language = "English",
volume = "128",
pages = "54--83",
journal = "Advanced Drug Delivery Reviews",
issn = "0169-409X",
publisher = "Elsevier Scientific Publ. Co",

}

TY - JOUR

T1 - Current developments and applications of microfluidic technology toward clinical translation of nanomedicines

AU - Liu, Dongfei

AU - Zhang, Hongbo

AU - Fontana, Flavia

AU - Hirvonen, Jouni Tapio

AU - Almeida Santos, Helder

PY - 2018/3/15

Y1 - 2018/3/15

N2 - Nanoparticulate drug delivery systems hold great potential for the therapy of many diseases, especially cancer. However, the translation of nanoparticulate drug delivery systems from academic research to the industrial and clinical practice has been slow. This slow translation can be ascribed to the high batch-to-batch variations and insufficient production rate of the conventional methods, and the lack of technologies for rapid screening of nanoparticulate drug delivery systems with high correlation to the in vivo tests. These issues can be addressed by the microfluidic technologies. For example, microfluidics can not only produce nanoparticles in a well-controlled, reproducible, and high-throughput manner, but also create 3D environments with continuous flow to mimic the physiological and/or pathological processes. This review provides an overview of the microfluidic devices developed to prepare nanoparticulate drug delivery systems, including drug nanosuspensions, polymer nanoparticles, polyplexes, structured nanoparticles and theranostic nanoparticles. We also highlight the recent advances of microfluidic systems in fabricating the increasingly realistic models of the in vivo milieu for rapid screening of nanoparticles. Overall, the microfluidic technologies offer a promise approach to accelerate the clinical translation of nanoparticulate drug delivery systems.

AB - Nanoparticulate drug delivery systems hold great potential for the therapy of many diseases, especially cancer. However, the translation of nanoparticulate drug delivery systems from academic research to the industrial and clinical practice has been slow. This slow translation can be ascribed to the high batch-to-batch variations and insufficient production rate of the conventional methods, and the lack of technologies for rapid screening of nanoparticulate drug delivery systems with high correlation to the in vivo tests. These issues can be addressed by the microfluidic technologies. For example, microfluidics can not only produce nanoparticles in a well-controlled, reproducible, and high-throughput manner, but also create 3D environments with continuous flow to mimic the physiological and/or pathological processes. This review provides an overview of the microfluidic devices developed to prepare nanoparticulate drug delivery systems, including drug nanosuspensions, polymer nanoparticles, polyplexes, structured nanoparticles and theranostic nanoparticles. We also highlight the recent advances of microfluidic systems in fabricating the increasingly realistic models of the in vivo milieu for rapid screening of nanoparticles. Overall, the microfluidic technologies offer a promise approach to accelerate the clinical translation of nanoparticulate drug delivery systems.

KW - 317 Pharmacy

KW - High throughput prepar ation

KW - Lab-on-a-chip

KW - Nanomedicines

KW - Drug delivery

KW - Organ-on-a-chip

KW - Formulation screening

KW - ON-A-CHIP

KW - BLOCK-COPOLYMER NANOPARTICLES

KW - CONFINED IMPINGING JETS

KW - CEFUROXIME AXETIL NANOPARTICLES

KW - POLYMER HYBRID NANOPARTICLES

KW - PARTICLE-CELL INTERACTIONS

KW - HIGH-THROUGHPUT PRODUCTION

KW - DRUG-LOADED NANOPARTICLES

KW - GAS-LIQUID FLOW

KW - IN-VIVO

KW - High throughput preparation

KW - Lab-on-a-chip

KW - Nanomedicines

KW - Drug delivery

KW - Organ-on-a-chip

KW - Formulation screening

KW - ON-A-CHIP

KW - BLOCK-COPOLYMER NANOPARTICLES

KW - CONFINED IMPINGING JETS

KW - CEFUROXIME AXETIL NANOPARTICLES

KW - POLYMER HYBRID NANOPARTICLES

KW - PARTICLE-CELL INTERACTIONS

KW - HIGH-THROUGHPUT PRODUCTION

KW - DRUG-LOADED NANOPARTICLES

KW - GAS-LIQUID FLOW

KW - IN-VIVO

UR - https://www.journals.elsevier.com/advanced-drug-delivery-reviews

U2 - 10.1016/j.addr.2017.08.003

DO - 10.1016/j.addr.2017.08.003

M3 - Review Article

VL - 128

SP - 54

EP - 83

JO - Advanced Drug Delivery Reviews

JF - Advanced Drug Delivery Reviews

SN - 0169-409X

ER -